ES2193751T3 - Delta3-piperidinas triciclicas como antagonistas alfa2. - Google Patents
Delta3-piperidinas triciclicas como antagonistas alfa2.Info
- Publication number
- ES2193751T3 ES2193751T3 ES99950627T ES99950627T ES2193751T3 ES 2193751 T3 ES2193751 T3 ES 2193751T3 ES 99950627 T ES99950627 T ES 99950627T ES 99950627 T ES99950627 T ES 99950627T ES 2193751 T3 ES2193751 T3 ES 2193751T3
- Authority
- ES
- Spain
- Prior art keywords
- antagonists
- norepinephrine
- central
- triciclic
- piperidins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000004659 Presynaptic Receptors Human genes 0.000 abstract 1
- 108010003717 Presynaptic Receptors Proteins 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 abstract 1
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003957 neurotransmitter release Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a Delta-3-piperidinas tricíclicas que tienen actividad antagonista de los receptores adrenérgicos La misma se refiere adicionalmente a su preparación, composiciones que las contienen y su uso como medicamento. Es sabido que los antagonistas centrales de los receptores adrenérgicos aumentan la liberación de noradrenalina por bloqueo de los receptores presinápticos que ejercen un control inhibidor sobre la liberación del neurotransmisor. Por aumentar las concentraciones de noradrenalina, los antagonistas pueden utilizarse clínicamente para el tratamiento o la profilaxis de la depresión, las alteraciones cognitivas, la enfermedad de Parkinson, la diabetes mellitus, la disfunción sexual y la impotencia, la presión intraocular elevada, y enfermedades relacionadas con enteroquinesia alterada, dado que todas estas condiciones están asociadas con una deficiencia de noradrenalina en el sistema nervioso central o periférico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203370 | 1998-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2193751T3 true ES2193751T3 (es) | 2003-11-01 |
Family
ID=8234191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99950627T Expired - Lifetime ES2193751T3 (es) | 1998-10-06 | 1999-10-01 | Delta3-piperidinas triciclicas como antagonistas alfa2. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6495555B1 (es) |
| EP (1) | EP1119571B1 (es) |
| JP (1) | JP4590101B2 (es) |
| KR (1) | KR20010071843A (es) |
| CN (1) | CN1131230C (es) |
| AR (1) | AR024216A1 (es) |
| AT (1) | ATE232869T1 (es) |
| AU (1) | AU760502B2 (es) |
| BG (1) | BG64872B1 (es) |
| BR (1) | BR9913507A (es) |
| CA (1) | CA2345622C (es) |
| CZ (1) | CZ20011104A3 (es) |
| DE (1) | DE69905478T2 (es) |
| DK (1) | DK1119571T3 (es) |
| EE (1) | EE04770B1 (es) |
| ES (1) | ES2193751T3 (es) |
| HU (1) | HUP0104002A3 (es) |
| ID (1) | ID28032A (es) |
| IL (1) | IL142443A0 (es) |
| NO (1) | NO20011270D0 (es) |
| NZ (1) | NZ510115A (es) |
| PL (1) | PL347894A1 (es) |
| PT (1) | PT1119571E (es) |
| RU (1) | RU2230744C2 (es) |
| SI (1) | SI1119571T1 (es) |
| SK (1) | SK285585B6 (es) |
| TR (1) | TR200100952T2 (es) |
| TW (1) | TWI248441B (es) |
| UA (1) | UA69420C2 (es) |
| WO (1) | WO2000020421A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4590102B2 (ja) * | 1998-10-06 | 2010-12-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 医薬としての三環性δ３−ピペリジン類 |
| AU2003219199A1 (en) * | 2002-04-03 | 2003-10-13 | Orion Corporation | Use of an alfa2-adrenoreceptor antagonist for cns-related diseases |
| AU2005233456A1 (en) | 2004-04-12 | 2005-10-27 | Taisho Pharmaceutical Co., Ltd. | Cyclic amine compound |
| US20060035939A1 (en) * | 2004-07-14 | 2006-02-16 | Japan Tobacco Inc. | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| WO2006006741A1 (ja) * | 2004-07-15 | 2006-01-19 | Japan Tobacco Inc. | 縮合ベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| NZ596137A (en) | 2009-05-14 | 2013-08-30 | Janssen Pharmaceutica Nv | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
| WO2015091414A2 (de) | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituierte piperidinyl-tetrahydrochinoline |
| EP3083610A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten |
| KR20160098424A (ko) * | 2013-12-19 | 2016-08-18 | 바이엘 파마 악티엔게젤샤프트 | 치환된 피페리디닐-테트라히드로퀴놀린 |
| CN114276359B (zh) * | 2022-01-05 | 2023-05-05 | 浙江大学 | 一种1,2,3,4-四氢苯并[4,5]呋喃[2,3-c]吡啶衍生物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU926914A1 (ru) * | 1980-05-26 | 1992-04-23 | Научно-исследовательский институт фармакологии АМН СССР | Производные 1,2,3,4-тетрагидробензофуро[3,2-с]-пиридина или хлоргидрат, обладающие р дом свойств анальгетиков и антагонистов морфина |
| DE3522959A1 (de) * | 1985-06-27 | 1987-01-08 | Merck Patent Gmbh | Indolderivate |
| US4673680A (en) * | 1985-09-18 | 1987-06-16 | Pendleton Robert G | α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility |
| EP0339959A3 (en) * | 1988-04-27 | 1991-03-20 | Glaxo Group Limited | Lactam derivatives |
| US4971974A (en) | 1988-06-16 | 1990-11-20 | Neurex Corporation | Benzothiophenes as appetite suppressants |
| US5100891A (en) * | 1991-01-18 | 1992-03-31 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[B]indoles and related compounds |
| ES2168682T3 (es) * | 1996-12-06 | 2002-06-16 | Abbott Lab | Compuestos alfa-1 adrenergicos a base de benzopiranopirrol y de benzopiranopiridina. |
| ES2238778T3 (es) | 1997-12-25 | 2005-09-01 | Meiji Seika Kaisha, Ltd. | Derivados de tetrahidrobenzoindol. |
| JP4590102B2 (ja) * | 1998-10-06 | 2010-12-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 医薬としての三環性δ３−ピペリジン類 |
-
1999
- 1999-01-10 UA UA2001031999A patent/UA69420C2/uk unknown
- 1999-10-01 CZ CZ20011104A patent/CZ20011104A3/cs unknown
- 1999-10-01 CN CN99811682A patent/CN1131230C/zh not_active Expired - Fee Related
- 1999-10-01 SI SI9930264T patent/SI1119571T1/xx unknown
- 1999-10-01 CA CA002345622A patent/CA2345622C/en not_active Expired - Fee Related
- 1999-10-01 IL IL14244399A patent/IL142443A0/xx not_active IP Right Cessation
- 1999-10-01 RU RU2001111812/04A patent/RU2230744C2/ru not_active IP Right Cessation
- 1999-10-01 AU AU63341/99A patent/AU760502B2/en not_active Ceased
- 1999-10-01 ID IDW20010780A patent/ID28032A/id unknown
- 1999-10-01 NZ NZ510115A patent/NZ510115A/xx unknown
- 1999-10-01 PT PT99950627T patent/PT1119571E/pt unknown
- 1999-10-01 EE EEP200100209A patent/EE04770B1/xx not_active IP Right Cessation
- 1999-10-01 DE DE69905478T patent/DE69905478T2/de not_active Expired - Lifetime
- 1999-10-01 TR TR2001/00952T patent/TR200100952T2/xx unknown
- 1999-10-01 AT AT99950627T patent/ATE232869T1/de not_active IP Right Cessation
- 1999-10-01 DK DK99950627T patent/DK1119571T3/da active
- 1999-10-01 US US09/806,547 patent/US6495555B1/en not_active Expired - Lifetime
- 1999-10-01 PL PL99347894A patent/PL347894A1/xx not_active Application Discontinuation
- 1999-10-01 BR BR9913507-8A patent/BR9913507A/pt not_active IP Right Cessation
- 1999-10-01 EP EP99950627A patent/EP1119571B1/en not_active Expired - Lifetime
- 1999-10-01 HU HU0104002A patent/HUP0104002A3/hu unknown
- 1999-10-01 TW TW088116898A patent/TWI248441B/zh not_active IP Right Cessation
- 1999-10-01 SK SK432-2001A patent/SK285585B6/sk unknown
- 1999-10-01 ES ES99950627T patent/ES2193751T3/es not_active Expired - Lifetime
- 1999-10-01 JP JP2000574533A patent/JP4590101B2/ja not_active Expired - Fee Related
- 1999-10-01 KR KR1020017000442A patent/KR20010071843A/ko not_active Ceased
- 1999-10-01 WO PCT/EP1999/007419 patent/WO2000020421A2/en not_active Ceased
- 1999-10-05 AR ARP990105038A patent/AR024216A1/es not_active Application Discontinuation
-
2001
- 2001-03-12 BG BG105332A patent/BG64872B1/bg unknown
- 2001-03-13 NO NO20011270A patent/NO20011270D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3041966T3 (en) | Use of cannabidiol in combination with norfenfluramine or fenfluramine in the treatment of epilepsy | |
| Kennett et al. | Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action | |
| Hsu | Xylazine-induced delay of small intestinal transit in mice | |
| Bymaster et al. | New approaches to developing antidepressants by enhancing monoaminergic neurotransmission | |
| BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
| Shimizu et al. | Dimethylsulfoxide (DMSO) treatment reduces infarction volume after permanent focal cerebral ischemia in rats | |
| BRPI0821683B8 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
| UY26974A1 (es) | Agonistas del receptor beta3 adrenérgico y usos de los mismos | |
| UY28150A1 (es) | Agentes terapeuticos | |
| CR8191A (es) | Derivados 3-amino croman y 2-amino tetralin | |
| AR023715A1 (es) | Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel | |
| AR021893A1 (es) | Compuesto de 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanona sustituida , su uso para la manufactura de un medicamento en el tratamiento de algunos trastornos del sistema nervioso central y periférico y composiciones farmacéuticas que las contienen | |
| UY27023A1 (es) | Derivados de fenil cetonas sustituidas como antagonistas de ip | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| BR0312169A (pt) | Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação | |
| ATE290910T1 (de) | Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| PE20080941A1 (es) | Compuestos triciclicos como agonistas del receptor de melatonina | |
| CL2009000980A1 (es) | Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006). | |
| Alvaro et al. | Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy | |
| US9023788B2 (en) | Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
| UY28377A1 (es) | Agentes terapeuticos | |
| BR0208405A (pt) | Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças | |
| BRPI0413013A (pt) | composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças | |
| ES2177543T3 (es) | Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. |